A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Different Concentrations of ZYG24002 Lotion in Adult Patients With Mild to Moderate Seborrheic Dermatitis
Latest Information Update: 22 Jun 2026
At a glance
- Drugs ZYG 24002 (Primary)
- Indications Seborrhoeic dermatitis
- Focus Adverse reactions
- Sponsors Sinomune
Most Recent Events
- 17 Jun 2026 Status changed from not yet recruiting to recruiting.
- 23 Apr 2026 Planned primary completion date changed from 30 Sep 2026 to 31 Dec 2026.
- 23 Apr 2026 Planned initiation date changed from 27 Feb 2026 to 10 May 2026.